The Pharma Data

DECEMBER 10, 2020

executive vice president of research and development. “We We look forward to working closely with the FDA throughout the clinical development process to bring this potential new innovative treatment to patients as quickly as possible.”. Safe Harbor Statement.

Containment 52

Containment Clinical Development Development Protein 52

Drug Discovery World

MARCH 14, 2023

TT-P34 was developed from the sortilin-related Vps10p domain containing receptor (SorCS2) receptor and acts by targeting the three major pathophysiological hallmarks of neurodegeneration: mitochondrial failure, lysosomal dysfunction, and loss of pro-survival signaling.

Life Science 52

Life Science Clinical Development Development Drugs 52

Drug Discovery World

JANUARY 19, 2023

Sustained reduction in endotoxin levels One of the metabolic characteristics of bacterial or virus infections is the strong decrease of circulating lipoprotein and particularly the High-Density Lipoprotein (HDL) with its main containing protein apolipoprotein A-I (apoA-I).

Drugs 52

Drugs Trials Clinical Trials Clinical Trials 52

Pfizer

AUGUST 3, 2022

Based on these results, the Phase 3 trial and further development of PF-07265803 will be discontinued. mitogen activated protein kinase pathway, which demonstrated improvement in functional capacity (6-minute walk test; 6MWT) in a 48-week, open-label, Phase 2 study among patients with symptomatic LMNA-related DCM. Disclosure Notice.

Development 101

Development Vaccination Vaccine Production 101

The Pharma Data

JANUARY 10, 2021

PLANEGG / MUNICH, GERMANY / ACCESSWIRE / January 11, 2021 / MorphoSys AG (FSE: MOR; Prime Standard Segment; MDAX & TecDAX; NASDAQ: MOR), a commercial-stage biopharmaceutical company and a leader in antibody, protein and peptide technologies, announced today that Jean-Paul Kress, M.D.,

Containment 52

Containment Clinical Development Antibody Development 52

The Pharma Data

JANUARY 13, 2021

HPN217, a tri-specific T cell activating recombinant protein construct (TriTAC®) targets B-cell maturation antigen (BCMA), a well-validated antigen expressed on malignant multiple myeloma cells. This press release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995.

Drugs 52

Drugs Clinical Trials Clinical Trials Containment 52

pharmaphorum

SEPTEMBER 1, 2020

The vaccine is still the frontrunner in a list of 30 COVID-19 vaccines in clinical development maintained by the World Health Organization. The virus contains genetic material of the SARS-CoV-2 spike protein, priming the immune system to attack the SARS-CoV-2 coronavirus if it later infects the body.

Vaccination 69

Vaccination Vaccine Trials Immune Response 69

The Pharma Data

NOVEMBER 9, 2020

Currently in late-phase clinical development, NVXCoV2373 is a stable, prefusion protein made using Novavax’ nanoparticle technology and includes its proprietary MatrixM adjuvant. NVX-CoV2373 contains purified protein antigen and cannot replicate, nor can it cause COVID-19.

Vaccination 52

Vaccination Vaccine Clinical Trials Clinical Trials 52

The Pharma Data

OCTOBER 25, 2020

We are advancing the clinical development of mRNA-1273 with our Phase 3 COVE study, which is now fully enrolled with a representative demography of participants across ages, ethnicities and high-risk populations. About Moderna. Moderna has been named a top biopharmaceutical employer by Science for the past five years.

Vaccination 52

Vaccination Vaccine Manufacturing Clinical Development 52

The Pharma Data

JANUARY 4, 2021

In addition, it has discovered and is developing the Outer Membrane Protein Targeting Antibiotics (OMPTA). OMPTA are potentially the first new class of antibiotics in clinical development in the last 50 years against Gram-negative bacteria. For more information, please visit www.polyphor.com.

Bacteria 52

Bacteria Containment Development Protein 52

XTalks

NOVEMBER 6, 2020

We are exceptionally pleased to commence dosing of our oral DNA vaccine for COVID-19 as we continue scale-up and manufacturing activities for future clinical development,” Symvivo’s chief medical officer Eric Sievers said in a press release from the company. Related: Red Meat Allergy Test Gets FDA Clearance. “We

Clinical Trials 75

Clinical Trials Clinical Trials Vaccination Vaccine 75

pharmaphorum

OCTOBER 14, 2021

The protein, Programmed Death-Ligand 1 (PD-L1), is found on the surface of many cells throughout the body. Some cancer cells contain large amounts of PD-L1, which helps them to evade the body’s immune system.

HR 45

HR Containment Protein Clinical Development 45

Pfizer

FEBRUARY 16, 2023

While VLA15 is still under investigation, to date the companies have been encouraged by the data from the Phase 2 clinical studies, which demonstrated strong immunogenicity and acceptable safety and tolerability profiles. 2-4 About VLA15 VLA15 is the only Lyme disease vaccine candidate currently in clinical development.

Clinical Trials 76

Clinical Trials Clinical Trials Vaccination Vaccine 76

The Pharma Data

JULY 15, 2021

ATTR amyloidosis is a rare, progressive and fatal disease characterised by the abnormal build-up of amyloid deposits composed of misfolded transthyretin protein in organs and tissues, most commonly the heart and/or nervous system.

Antibody 52

Antibody Protein Sales Development 52

The Pharma Data

DECEMBER 21, 2020

Targeted protein degradation (TPD) is an approach whereby the body’s natural process for degrading proteins is diverted using small molecule drugs to eliminate disease-causing proteins. However, there has so far been limited progress in applying this exciting approach to membrane-associated proteins such as GPCRs.

Drugs 40

Drugs Protein Development Production 40

The Pharma Data

OCTOBER 28, 2020

Over the past nine years, Moderna has invested in creating and developing a novel platform for designing and manufacturing a new class of mRNA-based vaccines. A summary of the company’s work to date on COVID-19 can be found here. mRNA-1273 currently is not approved for use by any regulatory body. Forward-Looking Statements.

Vaccination 40

Vaccination Vaccine Manufacturing Clinical Trials 40

The Pharma Data

DECEMBER 13, 2020

In addition, it has discovered and is developing the Outer Membrane Protein Targeting Antibiotics (OMPTA). OMPTA are potentially the first new class of antibiotics in clinical development in the last 50 years against Gram-negative bacteria. For more information, please visit www.polyphor.com.

Clinical Trials 52

Clinical Trials Clinical Trials Trials Bacteria 52

The Pharma Data

OCTOBER 18, 2020

About MorphoSys MorphoSys (FSE & NASDAQ: MOR) is a commercial-stage biopharmaceutical company dedicated to the discovery, development and commercialization of exceptional, innovative therapies for patients suffering from serious diseases. The focus is on cancer. Tremfya (R) is a registered trademark of Janssen Biotech, Inc.

Clinical Development 40

Clinical Development Antibody Development Production 40

XTalks

FEBRUARY 3, 2021

Biotech company Novavax (Nasdaq: NVAX ) reported that its protein-based vaccine demonstrated an efficacy of 89.3 Novavax’s Protein Vaccine. Of the leading vaccine candidates, Novavax’s shot (NVX-CoV2373) is one of the first protein vaccines in late-stage trials for COVID-19. variant that first popped up in the country.

Vaccination 103

Vaccination Vaccine Trials Protein 103

Pfizer

NOVEMBER 2, 2022

The vaccine candidate combines Pfizer’s quadrivalent modRNA-based influenza vaccine candidate, qIRV (22/23), which is currently in Phase 3 clinical development , and Pfizer and BioNTech’s authorized Omicron-adapted bivalent COVID-19 BNT162b2 (Original/Omicron BA.4/BA.5) COMIRNATY® (COVID-19 Vaccine, mRNA). INDICATION.

Vaccination 85

Vaccination Vaccine Clinical Trials Clinical Trials 85

The Pharma Data

JANUARY 3, 2021

The Phase 1/2 clinical trial will primarily investigate the safety and tolerability of INZ-701 and characterize its pharmacokinetic and pharmacodynamic profile, including plasma pyrophosphate (PPi) and other biomarker levels, to establish a recommended dosing regimen for further clinical development. About INZ-701.

Clinical Trials 52

Clinical Trials Clinical Trials Trials Containment 52

The Pharma Data

JANUARY 25, 2021

“The technology has a unique pharmacological profile, which is very different from other products in preclinical and clinical development in that it focuses on restoring function. The Company is developing drugs for the treatment of multiple sclerosis, spinal cord injury and Alzheimer’s disease.

Clinical Development 40

Clinical Development Containment Development Research 40

The Pharma Data

JANUARY 18, 2021

“The strong support of our syndicate reflects strong conviction in Vera’s clinical development experience and the potential of our lead asset to target the source of immune complexes in patients with IgAN and change the standard of care,” said founder and CEO Marshall Fordyce , MD.

Development 52

Development Life Science Protein Clinical Development 52

The Pharma Data

NOVEMBER 25, 2020

technology platform simultaneously identifies both targets and the antibodies that bind to them, generating many promising new drug candidates to fuel the Company’s own clinical development pipeline or for additional licensing and partnering. The Company’s validated, proprietary F.I.R.S.T About Cantargia.

Antibody 52

Antibody Manufacturing Clinical Trials Clinical Trials 52

The Pharma Data

DECEMBER 10, 2020

The vaccine targeted both the inner nucleocapsid (N) and the outer spike (S) proteins of the virus to maximize the immune response. ImmunityBio’s platform is based on the foundation of three separate modalities: antibody cytokine fusion proteins, synthetic immunomodulators, and second-generation human adenovirus (hAd5) vaccine technologies.

Vaccination 52

Vaccination Vaccine Immune Response Protein 52

The Pharma Data

JULY 18, 2021

That’s why we set out to develop a conjugate vaccine that includes pneumococcal serotypes that pose the greatest threat and elicits a strong immune response to each serotype covered,” said Dr. Roy Baynes, senior vice president and head of global clinical development, chief medical officer, Merck Research Laboratories.

Immune Response 52

Immune Response Vaccination Vaccine FDA Approval 52

XTalks

OCTOBER 26, 2023

She has 23 years of experience working with clients to move vaccine candidates through the clinical development pipeline, including regulatory submission. The Flu versus COVID-19: Virology and Vaccines SARS-CoV-2 versus Influenza Virology Viruses contain genetic material that can either be RNA or DNA.

Vaccination 105

Vaccination Vaccine RNA Manufacturing 105

Pfizer

DECEMBER 8, 2022

The vaccine candidate is based on BioNTech’s proprietary mRNA platform technology and contains mRNA strands encoding the wild-type spike protein of SARS-CoV-2 and the spike protein of the Omicron sublineages BA.4/BA.5, The information contained in this release is as of December 9, 2022. INDICATION.

Vaccination 81

Vaccination Vaccine Clinical Trials Clinical Trials 81

The Pharma Data

JANUARY 14, 2021

By tackling the tough scientific questions and untapped pathways, we aim to offer new hope by developing novel, breakthrough therapies that have potential to alter the course of disease in cancers with few treatment options. This vision is what defines us and guides our research, clinical development and partnerships.

Trials 52

Trials HR Containment Development 52

The Pharma Data

OCTOBER 19, 2020

“Pneumococcal disease in adults is on the rise globally, in part driven by disease-causing serotypes not targeted by the currently available pneumococcal conjugate vaccine,” said Dr. Roy Baynes, senior vice president and head of global clinical development, chief medical officer, Merck Research Laboratories. About Pneumococcal Disease.

Vaccination 52

Vaccination Vaccine Immune Response Containment 52

The Pharma Data

SEPTEMBER 8, 2020

Together, these nine companies have collectively developed more than 70 novel vaccines that have helped to eradicate some of the world’s most complex and deadly public health threats, underscoring their experience in clinical development and regulatory rigor, as well as their longstanding commitments to patient safety and public health.

Vaccination 52

Vaccination Vaccine Containment Clinical Trials 52

The Pharma Data

DECEMBER 2, 2020

Hemophilia is a genetic hematological rare disease that results in a deficiency of a protein that is required for normal blood clotting—clotting factor VIII in hemophilia A and clotting factor IX in hemophilia B. PFIZER DISCLOSURE NOTICE: The information contained in this release is as of November 23, 2020. About Hemophilia.

Containment 52

Containment Development Clinical Trials Clinical Trials 52

The Pharma Data

SEPTEMBER 8, 2020

Together, these nine companies have collectively developed more than 70 novel vaccines that have helped to eradicate some of the world’s most complex and deadly public health threats, underscoring their experience in clinical development and regulatory rigor, as well as their longstanding commitments to patient safety and public health.

Vaccination 52

Vaccination Vaccine Containment Clinical Trials 52

Pfizer

SEPTEMBER 28, 2022

Monovalent refers to any authorized and approved COVID-19 vaccine that contains or encodes the spike protein of only the Original SARS-CoV-2 virus . The information contained in this release is as of September 28, 2022. . • receipt of the most recent booster dose with any authorized or approved monovalent COVID-19 vaccine. .

Vaccination 101

Vaccination Vaccine Medicine Clinical Trials 101

The Pharma Data

NOVEMBER 20, 2020

Zokinvy blocks the accumulation of defective, farnesylated proteins which form tight associations with the nuclear envelope, leading to cellular instability and the process of premature aging in children and young adults with Progeria and processing-deficient Progeroid Laminopathies. ABOUT ZOKINVY (LONAFARNIB). LIMITATIONS OF USE.

FDA Approval 52

FDA Approval Genetics Clinical Trials Clinical Trials 52

The Pharma Data

NOVEMBER 4, 2020

Ltd (“Juyou”), a biotechnology company that develops and sells medical and cosmetic skincare products, for the commercialization and development of Pliaglis ® in mainland China (the “License Agreement”). For additional information, please visit [link].

Licensing 40

Licensing Licensing Dermatology Production 40

The Pharma Data

NOVEMBER 19, 2020

Program focused on inhibitors of SARS-CoV-2 main protease, a highly conserved protein essential for viral replication. Structure-based design approach has identified potent compounds for further development as oral treatments for SARS-CoV-2 infection and related human coronaviruses.

Development 40

Development Bioavailability Production Drugs 40